Marinus Pharma (MRNS) Reports First Patient Enrollment in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus

Go back to Marinus Pharma (MRNS) Reports First Patient Enrollment in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus

Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus

January 26, 2021 7:01 AM EST

Marinus and Ceribell, Inc. agree to place handheld Ceribell Rapid Response EEG systems in hospitals in connection with its Phase 3 RSE clinical trial

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure... More